Fifty years of "the pill": Risk reduction and discovery of benefits beyond contraception, reflections, and forecast

Toxicological Sciences

Volumn 125, Issue 1, 2012, Pages 2-9

  Chadwick, Kristina D ^a   Burkman, Ronald T ^b   Tornesi, Belen M ^c   Mahadevan, Brinda ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b BAYSTATE MEDICAL CENTER   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Oral contraceptive; Risk reduction; Safety

Indexed keywords

DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTRACEPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; FAMILY PLANNING; GENOMICS; HEART INFARCTION; HUMAN; MENSTRUAL CYCLE; MONOTHERAPY; OVULATION; PREGNANCY; PROTEOMICS; REPRODUCTION; RISK REDUCTION; STROKE; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84555178258     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr242     Document Type: Article

References (50)

1. Abma, J. C., Chandra, A., and Mosher, W. D. (1995). Fertility, family planning and women's health: New data from the 1995 Survey of Family Growth. Vital Health Stat. 23, 19.
2. American College of Obstetricians and Gynecologists Practice Bulletin. (2010). Emergency contraception. Obstet. Gynecol. 115, 1100-1109.
3. American College of Obstetricians and Gynecologists Practice Bulletin. (2011). Long-acting reversible contraception: Implants and intrauterine devices. Obstet. Gynecol. 118, 184-196.
4. Anderson, R. A., and Baird, D. T. (2002). Male contraception. Endocr. Rev. 23, 735-762.
5. Betz, S. F., Zhu, Y. F., Chen, C., and Struthers, R. S. (2008). Non-peptide gonadotropin-releasing hormone receptor antagonists. J. Med. Chem. 51, 12.
6. Burkman, R. T. (2004). Safety concerns and health benefits associated with oral contraception. Am. J. Obstet. Gynecol. 190, S5-S22.
7. Calaf, I., and Alsina, J. (2010). After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur. J. Contracept. Reprod. Health Care 15, S9-S11.
8. CCCC. (1999). Consensus conference on combination oral contraceptives and cardiovascular disease. Fertil. Steril. 71, 1S-6S.
9. Corson, S. L. (1996). Increased risk from third-generation progestogens: Fuzzy logic or fuzzy science? J. Reprod. Med. 4, 711-712.
10. Croft, P., and Hannaford, P. (1989). Risk factors for acute myocardial infarction in women. BMJ 298, 674.
11. Dhont, M. (2010). History of oral contraception. Eur. J. Contracept. Reprod. Health Care 15, S12-S18.
12. Dunn, N. (2011). The risk of deep venous thrombosis with oral contraceptives containing drospirenone. BMJ 342, 2519.
13. Gerstman, B. B., Piper, J. M., Tomita, D. K., Ferguson, W. J., Stadel, B. V., and Lundin, F. E. (1991). Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am. J. Epidemiol. 133, 32-37.
14. Gioietta, K. (2010). In Male Contraception Proven Effective in Chinese Study. Available at: http://www.worldwatch.org/node/6364. Accessed February 11, 2011.
15. Goldbaum, G. M., Kendrick, J. S., Hogelin, G. C., and Gentry, E. M. (1987). The relative impact of smoking and oral contraceptive use on women in the United States. JAMA 258, 1339-1342.
16. Hannaford, P. C., Iversen, L., Macfarlane, T. V., Elliott, A. M., Angus, V., and Lee, A. J. (2010). Mortality among contraceptive pill users: Cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 340, c927. doi:10.1136/bmj.c927.
17. Henshaw, S. K. (1998). Unintended pregnancy in the United States. Fam. Plann. Perspect. 130, 24-46.
18. Jick, S. S., and Hernandez, R. K. (2011). Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: Case-control study using United States claims data. BMJ 342, d2151.
19. Jick, S. S., Kaye, J. A., Russmann, S., and Jick, H. (2006). Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 73, 566-570.
20. Lessard, C., Pendola, J. K., Hartford, S. A., Schimenti, J. C., Handel, M. A., and Eppig, J. J. (2004). New mouse genetic models for human contraceptive development. Cytogenet. Genome Res. 105, 222-227.
21. Lewis, M. A. (1998). The epidemiology of oral contraceptive use: A critical review of the studies on oral contraceptives and the health of young women. Am. J. Obstet. Gynecol. 179, 1086-1097.
22. Li, R., and Anderson, R. A. (2010). Recent advances in hormonal contraception. Med. Rep. 2, 58.
23. Lidegaard, Ø., Edstr̈m, B., and Kreiner, S. (2002). Oral contraceptives and venous thromboembolism: A five-year national case-control study. Contraception 65, 187-196.
24. Liu, G. Z., Lyle, K. C., and Cao, J. (1987). Clinical trials of gossypol as a male contraceptive drug. Part I. Efficacy study. Fertil. Steril. 48, 459-461.
25. Mann, J. I., and Inman, W. H. (1975). Oral contraceptives and death from myocardial infarction. BMJ 2, 245-248.
26. Mann, J. I., Vessey, M. P., Thorogood, M., and Doll, S. R. (1975). Myocardial infarction in young women with special reference to oral contraceptive practice. BMJ 2, 241-245.
27. Murphy, C. (2010, May). BBC News Health Report. Available at: http://news.bbc.co.uk/2/hi/8667418.stm. Accessed September 30, 2011.
28. Natraj, U. (2001). Molecular approaches to contraceptive development. J. Biosci. 26, 407-419.
29. Naz, R. K., Engle, A., and None, R. (2009). Gene knockouts that affect female fertility: Novel targets for contraception. Front. Biosci. 2, 1092-1112.
30. O'Rand, M. G., Widgren, E. E., Sivashanmugam, P., Richardson, R. T., Hall, S. H., French, F. S., VandeVoort, C. A., Ramachandra, S. G., Ramesh, V., and Jagannadha Rao, A. (2004). Reversible immunocontraception in male monkeys immunized with eppin. Science 306, 1189-1190.
31. Parkin, L., Sharples, K., Hernandez, R. K., and Jick, S. S. (2011). Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: Nested case-control study based on UK General Practice Research Database. BMJ 342, d2139.
32. Petitti, D. B., Sidney, S., Bernstein, A., Wolf, S., Quesenberry, C., and Ziel, H. K. (1996). Stroke in users of low-dose oral contraceptives. N. Engl. J. Med. 335, 8-15.
33. Pomp, E. R., le Cessie, S., Rosendaal, F. R., and Doggen, C. J. (2007). Risk of venous thrombosis: Obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br. J. Haematol. 139, 289-296.
34. Rosenberg, L., Kaufman, D. W., Helmrich, S. P., Miller, D. R., Stolley, P. D., and Shapiro, S. (1985). Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 253, 2965-2969.
35. Schwartz, S. M., Petitti, D. B., Siscovick, D. S., Longstreth, W. T., Sidney, S., Raghunathan, T. E., Quesenberry, C. P., and Kelaghan, J. (1998). Stroke and use of low-dose oral contraceptives in young women: A pooled analysis of two US studies. Stroke 29, 2277-2284.
36. Shafik, A. (1992). Contraceptive efficacy of polyester-induced azoospermia in normal men. Contraception 45, 439-451.
37. Sipila, P., Jalkanen, J., Huhtaniemi, I. T., and Poutanen, M. (2009). Novel epididymal proteins as targets for the development of post-testicular male contraception. Reproduction 137, 379-389.
38. Spitzer, W. O., Faith, J. M., and MacRae, K. D. (2002). Myocardial infarction and third generation oral contraceptives: Aggregation of recent studies. Hum. Reprod. 17, 2307-2314.
39. Struthers, R. S. (2005). Orally active non-peptide GnRH antagonists. The past and the future. Presented at the 8th International Symposium on GnRH Analogues, Salzburg, Austria.
40. Suissa, S., Blais, L., Spitzer, W. O., Cusson, J., Lewis, M., and Heinemann, L. (1997). First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 56, 141-146.
41. Suissa, S., Spitzer, W. O., Rainville, B., Cusson, J., Lewis, M., and Heinemann, L. (2000). Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum. Reprod. 15, 817-821.
42. Tanis, B. C., Maurice, A. A. J., Bosch, V. D., Kemmeren, J. M., Cats, V. M., Helmerhorst, F. M., Algra, A., Van Der Graaf, Y., and Rosendal, F. R. (2001). Oral contraceptives and the risk of myocardial infarction. N. Engl. J. Med. 345, 1787-1793.
43. Vandenbroucke, J. P., Koster, T., Briët, E., Reitsma, P. H., Bertina, R. M., and Rosendaal, F. R. (1994). Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344, 1453-1457.
44. Vessey, M., Mant, D., Smith, A., and Yeates, D. (1986). Oral contraceptives and venous thromboembolism: Findings in a large prospective study.BMJ292, 526.
45. Wang, C., McDonald, V., Leung, A., Superlano, L., Berman, N., Hull, L., and Swerdloff, R. S. (1997). Effect of increased scrotal temperature on sperm production in normal men. Fertil. Steril. 68, 334-339.
46. WHO Study-Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. (1996). Ischaemic stroke and combined oral contraceptives: Results of an international, multicentre, case-control study. Lancet 348, 498-505.
47. World Health Organization Working Group (WHO-WG). (1998). World Health Organization Working Group, Cardiovascular Disease and Steroid Hormone Contraception. World Health Organization, Geneva, Switzerland.
48. Williams, C. L., and Stancel, G. M. (1996). Estrogens and progestins. In Goodman and Gilmans' The Pharmacological Basis of Therapeutics (J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, and A. Goodman Gilman, Eds.), 9th ed. pp. 1431-1437. McGraw-Hill, New York, NY.
49. Winkler, U. H. (1998). Blood coagulation and oral contraceptives. A critical review. Contraception 57, 203-209.
50. Zhou, C. X., Zhang, Y., Xiao, L., Zheng, M., Leung, K. M., Chan, M. Y., Lo, P. S., Tsang, L. L., Wong, H. Y., Ho, L. S., et al. (2004). An epididymisspecific B-defensin is important for sperm maturation. Nat. Cell Biol. 6, 458-464.